trifarotene   Click here for help

GtoPdb Ligand ID: 9962

Synonyms: Aklief® | CD5789 | compound 15b [PMID: 29706423]
Approved drug PDB Ligand Immunopharmacology Ligand
trifarotene is an approved drug (FDA (2019))
Compound class: Synthetic organic
Comment: Trifarotene (CD5789) is a RARγ-selective agonist that was developed as a topical anti-acne therapeutic [1-2,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 70
Molecular weight 459.24
XLogP 7.16
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OCCOc1ccc(cc1c1ccc(c(c1)C(C)(C)C)N1CCCC1)c1ccc(cc1)C(=O)O
Isomeric SMILES OCCOc1ccc(cc1c1ccc(c(c1)C(C)(C)C)N1CCCC1)c1ccc(cc1)C(=O)O
InChI InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
No information available.
Summary of Clinical Use Click here for help
Trifarotene (CD5789) has completed Phase 3 clinical trial in patients with acne vulgaris, including the long term safety study NCT02189629 [3]. FDA approval for clinical use in patients with acne was granted in October 2019 (for Aklief®, a 0.005% topically applied cream).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02189629 CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris Phase 3 Interventional Galderma R&D